Bay Colony Advisory Group Inc d b a Bay Colony Advisors Boosts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 25.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 856 shares of the pharmaceutical company’s stock after acquiring an additional 173 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Vertex Pharmaceuticals were worth $348,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC increased its position in Vertex Pharmaceuticals by 65.3% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock worth $920,000 after purchasing an additional 1,045 shares during the period. Robeco Institutional Asset Management B.V. increased its position in Vertex Pharmaceuticals by 6.5% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock worth $150,550,000 after purchasing an additional 26,523 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Vertex Pharmaceuticals by 1.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock worth $148,485,000 after purchasing an additional 5,514 shares during the period. Machina Capital S.A.S. acquired a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $816,000. Finally, Morgan Stanley increased its position in Vertex Pharmaceuticals by 3.2% during the 3rd quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock worth $998,050,000 after purchasing an additional 89,217 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.2 %

Shares of Vertex Pharmaceuticals stock opened at $397.36 on Tuesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $316.43 and a fifty-two week high of $448.40. The firm has a market cap of $102.70 billion, a PE ratio of 28.61, a P/E/G ratio of 2.16 and a beta of 0.35. The business’s fifty day moving average is $415.72 and its two-hundred day moving average is $396.46. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the company posted $3.33 EPS. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $440.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. HC Wainwright upped their price target on Vertex Pharmaceuticals from $457.00 to $462.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target on the stock in a report on Thursday, April 11th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $424.62.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock valued at $5,203,249 in the last quarter. 0.20% of the stock is currently owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.